Immunotherapeutic vaccine and antibody combination therapy
AssigneeTransgene S.A.
InventorsPhilippe Slos, Julie Hortelano, Karola Rittner, Xavier Preville
Life of this patent
Estimating the term…
Abstract
The present invention relates to a combination product, composition(s) and kit of parts comprising at least (i) a therapeutic vaccine and (ii) one or more immune checkpoint modulator(s). The present invention also concerns a method for treating a proliferative or an infectious disease as well as a method for eliciting or stimulating and/or re-orienting an immune response, wherein said methods comprise administering to a subject in need thereof said combination product or said composition(s).
Claims14
A method for treating a proliferative or an infectious disease comprising administering to a subject in need thereof an effective amount of a combination product comprising (i) a therapeutic vaccine and (ii) one or more immune checkpoint modulator(s);
- wherein said therapeutic vaccine comprises a modified vaccinia virus Ankara (MVA) encoding membrane anchored Human papilloma Viruses 16 (HPV-16) non-oncogenic E6 and E7 antigens and encoding interleukin 2 (IL-2);
- wherein said one or more immune checkpoint modulator(s) comprise(s) a modulator capable of antagonizing at least partially programmed cell death protein 1 (PD-1) pathway;
- and
- wherein said administering of said therapeutic vaccine starts before said administering of said one or more immune checkpoint modulator(s) and
- wherein said therapeutic vaccine is administered a first time in a first administration of said therapeutic vaccine separated by a period of time from a first administration of said one or more immune checkpoint modulator(s), and the period of time between the first administration of said therapeutic vaccine and the first administration of said one or more immune checkpoint modulator(s) is one day to eight week(s).
Dependencies are inferred from the claim text.